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Abstract
Background: Airway eosinophilia is considered a central event in the pathogenesis of asthma. Eotaxin plays a key
role in selective eosinophil accumulation in the airways and, subsequently, their activation and degranulation. The
study was undertaken to evaluate eotaxin-1 levels in the exhaled breath condensate (EBC) of asthmatics with
different degrees of asthma severity and to establish the possible correlation of these measurements with other
recognized parameters of airway inflammation.
Methods: EBC was collected from 46 patients with allergic asthma (14 with steroid-naïve asthma, 16 with ICS-
treated, stable asthma, 16 with ICS-treated unstable asthma) and 12 healthy volunteers. Concentrations of eotaxin-1
were measured by ELISA.
Results: In the three groups of asthmatics, eotaxin-1 concentrations in EBC were significantly higher compared
with healthy volunteers (steroid-naïve asthma: 9.70 pg/ml ± 1.70, stable ICS-treated asthma: 10.45 ± 2.00, unstable
ICS-treated asthma: 17.97 ± 3.60, healthy volunteers: 6.24 ± 0.70). Eotaxin-1 levels were significantly higher in
patients with unstable asthma than in the two groups with stable disease. We observed statistically significant
correlations between the concentrations of eotaxin-1 in EBC and exhaled nitric oxide (FENO) or serum eosinophil
cationic protein (ECP) in the three studied groups of asthmatics. We also discovered a significantly positive
correlation between eotaxin-1 in EBC and blood eosinophil count in the groups of patients with unstable asthma
and steroid-naïve asthma.
Conclusions: Measurements of eotaxin-1 in the EBC of asthma patients may provide another useful diagnostic tool
for detecting and monitoring airway inflammation and disease severity.
Introduction
Asthma is a chronic inflammatory disease of the air-
ways. Eosinophils play a crucial role in the pathogenesis
of asthma, and eosinophil infiltrations prevail in sites of
allergic inflammation. The most important factors tak-
ing part in the development of inflammatory infiltration
are increased expression of adhesion molecules localized
on the surface of endothelial cells (VCAM-1 - vascular
cell adhesion molecule-1) and increased synthesis of
chemotactic substances by eosinophils and Th2 lympho-
cytes [1,2]. Many factors are known which increase eosi-
nophil chemotaxis to the site of inflammation as well as
prolonging their survival, e.g. IL-3, IL-5, GM-CSF
(granulocyte monocyte colony stimulating factor) [3].
They act together with selective chemokines of eosino-
phils, such as eotaxin, RANTES or MCP-4 (monocyte
chemotactic protein-4). The strongest and the most
specific chemoattractant is eotaxin [1,2].
In previous studies it was revealed that eotaxin levels
in BAL fluid were higher in asthmatics than in healthy
controls [4,5]. Eotaxin concentrations in sputum were
also significantly raised in moderate and severe asthma
patients when compared with healthy controls [6]. How-
ever, these relatively invasive approaches are unsuitable
for repeated monitoring of airway inflammation.
By contrast, exhaled breath condensate (EBC), col-
lected by cooling exhaled air, is a noninvasive, easily
performed, and rapid method for obtaining samples
from the lower respiratory tract. There has been increas-
ing interest in measuring EBC, which is a very useful
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strategies for the treatment of asthma - especially for
the assessment of inflammatory mediators related to the
bronchial epithelium [7]. However, the analysis of EBC
is still in its experimental phase and there remain many
methodological questions in this method [8].
Previous studies have revealed that eotaxin can be
measured in the EBC of patients with asthma [9-11]. Ko
et al reveal that eotaxin levels are higher in asthmatics
treated with inhaled steroids than in steroid-naïve asth-
matics or healthy controls. The authors suggest that
exhaled chemokines may be potential non-invasive mar-
kers for assessing airway inflammation in asthmatics [9].
However, to confirm such usefulness for eotaxin, the
establishment of correlations of its levels with other
recognized markers in the assessment of eosinophilic
inflammation is needed. Such data are not available so
far in published studies.
We hypothesize that eotaxin-1 levels in EBC are asso-
ciated with the level of severity of the disease and mar-
kers of airway inflammation in asthma.
The aim of the study was to assess eotaxin-1 concen-
trations in the EBC of asthmatics with different degrees
of asthma severity, and also to establish the possible
correlation of these measurements with the other recog-
nized parameters of airway inflammation.
Material and methods
Study population
The study was performed upon groups of 14 steroid-
naïve allergic asthma patients; 16 patients, treated with
inhaled corticosteroids (ICS) with stable allergic asthma;
and 16 ICS-treated patients with unstable allergic
asthma. Asthma was diagnosed according to the criteria
recommended by the GINA 2006 [12].
The steroid-naïve asthmatics had not been treated
with ICS. They were free from acute exacerbations and
respiratory tract infections during the three months
prior to the study. In this group of patients asthma was
diagnosed recently, just before inclusion to the study
(on the basis of symptoms and other recognized tests,
such as reversibility test or/and bronchial provocation
tests).
The patients with unstable ICS-treated asthma and
stable ICS-treated asthma had a many-year history of
asthma and anti-asthmatic treatment. In these patients
asthma was diagnosed several years ago on the basis of
typical symptoms, positive reversibility tests, or bron-
chial provocation tests. The patients with stable ICS-
treated asthma had been treated with low to medium
doses of ICS at a constant dose for at least three
months. Stable asthma was defined as a minimal need
for rescue medications (short-acting b2-agonists), no
exacerbations, and no use of systemic steroids in the
previous 12 months. The patients with unstable asthma
had required one or more hospitalizations for asthma
and more than three oral steroid bursts in the last year.
They had been taking high-doses of ICS and long-acting
b2-agonists for at least six months. Patients who had
respiratory tract infections in the last month before the
s t u d yw e r ee x c l u d e df r o mt h i ss t u d y .A l lt h ep a t i e n t s
were atopic and sensitized to common perennial inhaled
allergens, as evaluated bys k i np r i c kt e s t s( w i t h
commonly encountered aeroallergens: house dust
mites, trees, weeds, grasses, cat, dog, Alternaria and
Cladosporium).
12 healthy subjects were recruited for the study as a
negative control group. In this group, asthma was
excluded on the basis of lack of symptoms of asthma
and atopy, normal spirometric indices, low exhaled
nitric oxide (FENO) levels, and no presence of eosinophi-
lia in peripheral blood. Healthy volunteers also had a
negative bronchial provocation test with histamine
(PC20 > 32 mg/ml). All healthy volunteers were non ato-
pic; all of them had negative skin prick tests. They were
free of respiratory tract infection within three months
prior to the study and from other significant illnesses
known to affect FENO measurements. Asthma patients
and healthy volunteers were non-smokers and during
the last year had not been passive smokers.
The scheme of the procedures during the study
After inclusion to the study, the history of every patient
with asthma was taken, then all patients were examined
by the physician and blood (to determine serum total
IgE, ECP, and blood eosinophil count) and EBC samples
were collected. After 30 min, the measurement of FENO
level and spirometry were performed. Subsequently, all
patients had skin prick tests. In healthy volunteers, all
these procedures were carried out in the similar
sequence. Finally, in all studied healthy subjects, a non-
specific bronchial provocation test with histamine was
performed.
The study protocol was approved by the Ethics of
Research Committee of the Medical University of Bialys-
tok, number of agreement: R-I-002/265/2009. Informed
consent was obtained from every patient entered in the
study.
Exhaled nitric oxide measurements
Exhaled nitric oxide (FENO) was measured by the chemi-
luminescence technique using a Sievers 280i NO Analy-
zer (Boulder, Colorado, USA). The measurements were
performed at an expiratory flow of 50 ml/s according to
ATS recommendations for on-line measurement of
FENO in adults [13].
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The spirometry (FEV1)w a sp e r f o r m e du s i n gaM a s -
terScreen Pneumo PC spirometer (Jaeger, Hoechberg,
Germany), according to ATS standards [14].
Collection of exhaled breath condensate
EBC was collected by using a commercially available
condenser (EcoScreen; Erich Jaeger GmbH, Hoechberg,
Germany) according to the current ATS/ERS guidelines
[7]. All measurements were performed at the same time
(between 8.00-10.00 am) to avoid possible circadian
rhythm of mediator concentrations in EBC. All patients
were asked to refrain from eating and drinking before
collecting EBC. Exhaled air entered and left the chamber
through one-way valves and an inlet and outlet, thus
keeping the chamber closed. A low temperature inside
the condensing chamber throughout the collection time
produced a cooling down sample. The temperature of
collection was around 0°C [7,15]. Patients were
instructed to breathe tidally for 10 minutes with nose
clip. The respiratory rate ranged from 15-20 breaths/
minute. Patients were asked to swallow their saliva peri-
odically and to temporarily discontinue collection if they
needed to cough. At the end of collection 1.5 to 3.5 ml
aliquots of condensate were transferred to Eppendorf
tubes and immediately frozen. Samples were stored at
-80°C [16].
The longest storage time of EBC samples did not
exceed two months. The samples were not concentrated
prior to measurement. All measurements were performed
in a blind fashion. All samples were run in duplicate.
Because the marker used to correct the difference in the
degree of dilution has not yet been established, in our
study we made no attempt to assess the dilution of ALF
in EBC. The results (eotaxin-1) were well repeatable {CV
(%) = 4-7%}. We performed the preliminary study, in
which we measured eotaxin-1 in EBC immediately after
collection and after 1, 2, and 3 months of storage at -80°
C and we did not observe important changes. Therefore,
we suggest that eotaxin-1 in EBC stored at -80°C remains
stable during at least three months.
Measurements of eotaxin-1, ECP and other laboratory
parameters
Serum total IgE concentrations and serum ECP were
measured using ImmunoCAP™ Technology (Pharmacia
Diagnostics, Uppsala, Sweden). The minimum detectable
level of ECP was 2.0 μg/l. Blood eosinophil count was
measured using a hematologic analyzer (Coulter Electro-
nics GmbH, Miami, Florida, USA). The concentrations
of eotaxin-1 (R&D Systems, Wiesbaden-Nordenstadt,
Germany) in EBC were determined using an enzyme-
linked immunosorbent assay. The minimum detectable
level was 5.0 pg/ml.
Statistical analysis
Statistical significance was analyzed by using analysis of
variance (ANOVA) followed by Bonferroni’s t test post
hoc to determine statistical differences. All values were
expressed as means ± SD; p values < 0.05 were consid-
ered significant. The relationship between studied para-
meters was assayed by correlation. Pearson’sl i n e a r
correlation coefficient was used.
Results
Characteristics of patients and healthy volunteers are
presented in table 1 (Table 1)
In the three groups of asthmatics, EBC concentrations
of eotaxin-1 were significantly higher than those
detected in healthy volunteers (steroid-naïve asthma:
9.70 pg/ml ± 1.70 [min. 7.56, max. 12.6], p = 0.002;
ICS-treated stable asthma: 10.45 ± 2.00 [min. 7.3, max.
13.8], p < 0.001; unstable ICS-treated asthma: 17.97 ±
3 . 6 0[ m i n .1 2 . 4 ,m a x .2 4 . 5 ] ,p<0 . 0 0 1 ;h e a l t h yv o l u n -
teers: 6.24 ± 0.70 [min. 5.4, max. 7.3]) (Figure 1).
Eotaxin-1 levels were elevated in patients with unstable
ICS-treated asthma compared with ICS-treated stable
asthma (p = 0.03) and steroid-naïve asthma patients
(p = 0.009). We observed a tendency toward slightly
lower eotaxin-1 concentrations in steroid-naïve asthma
patients compared with the ICS-treated stable asthma
group (p = 0.52).
We found statistically significant correlations between
the concentrations of eotaxin-1 in EBC and FENO in the
three studied groups of asthmatics. There were no cor-
relations between eotaxin-1 in EBC and FENO in the
group of healthy volunteers (Figure 2). We discovered a
significantly positive correlation between eotaxin-1 in
EBC and serum ECP or blood eosinophil count in the
groups of patients with unstable ICS-treated asthma and
steroid-naïve asthma and between eotaxin-1 and serum
ECP in the group of ICS-treated stable asthma (Figure
3, Figure 4). Statistically significant correlations between
eotaxin-1 in EBC and other studied parameters were
not observed in any studied groups of asthmatics or
healthy volunteers (Table 2).
Differences in eotaxin-1 levels (measured in dupli-
cates) against the mean, using Bland and Altman statis-
tics in the studied groups of asthmatic patients and
healthy volunteers are presented in figure 5.
Discussion
Airway eosinophilia is recognized as a central event in
the pathogenesis of asthma. The toxic components pro-
duced by eosinophils are thought to be important in
inducing damage and dysfunction of bronchial mucosa
[17]. Evidence suggests that recruitment of eosinophils
into sites of inflammation is a multifractorial and
multistep process, in which eosinophil-endothelial
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Characteristics Dimension Healthy
volunteers
Steroid naïve
asthma
Stable ICS-treated
asthma
Unstable ICS- treated
asthma
Number of patients 12 14 16 16
Sex F/M 6/6 8/6 9/7 10/6
Age Years 25.40 ± 5.20 25.00 ± 6.30 39.50 ± 10.70 45.80 ± 7.30
Duration of symptoms Years 2.71 ± 1.08
+Δ 10.80 ± 6.20*
Δ 17.06 ± 6.50*
+
Baseline FEV1 % pred 102.50 ± 9.1
+Δ 89.20 ± 12.00
Δ 80.80 ± 7.10
Δ 51.50 ± 11.70*
+
FEV1/FVC ratio % 86 ± 7 73 ± 8 64 ± 10 56 ± 12
Serum total IgE
concentration
kU/L 61.08 ± 25.50* 248.4 ± 202.3 232.5 ± 79.0 318.0 ± 98.0
Blood eosinophil count cells/mm
3 56 ± 22*
+Δ 212 ± 88 281 ± 73 302 ± 95
FENO ppB 15.80 ± 5.06* 75.21 ± 37.13
+ 39.40 ± 12.50*
Δ 64.70 ± 25.04
+
Eotaxin-1 (EBC) pg/ml 6.24 ± 0.70*
+Δ 9.70 ± 1.70
Δ 10.45 ± 2.00
Δ 17.97 ± 3.60*
+
ECP (serum) μg/l 3.87 ± 0.81* 13.21 ± 4.56 12.80 ± 3.50
Δ 21.90 ± 8.40*
+
ICS μg/day 359 ± 128 1078 ± 269
Positive SPT
mite/cat/moulds 14/2/3 14/4/4 15/4/6
Data are presented as medians (ranges)
FEV1- forced expiratory volume in one second
* Values significantly different from patients with steroid-naïve asthma, p < 0.05
+ Values significantly different from patients with stable, ICS-treated asthma, p < 0.05
Δ Values significantly different from patients with unstable, ICS-treated asthma, p < 0.05
ICS - inhaled corticosteroids (Fluticasone propionate equivalent)
SPT - skin prick tests (number of patients)
Figure 1 Concentrations of eotaxin in EBC in studied groups of asthma patients and healthy volunteers.
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eration of chemotactic agents that direct cell migration
into the inflamed airways, play an important role [18].
Therefore, adhesion molecules and chemokines are cru-
cial mediators in selective eosinophil accumulation. In
asthmatic patients, a relevant but variable correlation
between blood eosinophilia and degree of asthma sever-
ity or bronchial hyperreactivity can be observed [19].
Eotaxin is the most specific and the strongest factor
which can affect the function of eosinophil. The effect
of eotaxin can be observed at each stage of the life cycle
of eosinophil, and therefore plays a very important role
in the development of allergic reaction. This chemokine
is responsible for the release of progenitors of eosino-
phils from the bone marrow, and, together with IL-5,
increases the count of mature forms in peripheral blood.
The consequence of these processes is peripheral and
tissue eosinophilia [20]. The count of eosinophils in an
infiltrated organ is proportional to the concentrations of
eotaxin in the site. Eotaxin is responsible for retardation
of the apoptosis of eosinophils, and eotaxin interaction
with a receptor leads to their activation and degranula-
tion [2]. Eotaxin can also cause migration of mast cells
[21] and basophils [22].
Those human cells which can produce eotaxin are the
airway epithelium, endothelial cells, lymphocytes,
macrophages, and eosinophils, as well as airway smooth
muscle cells [2]. Eotaxin as a chemotactic factor for
eosinophils plays an important role in the pathogenesis
of asthma. It has been shown that eotaxin concentration
in plasma correlates with the degree of bronchial hyper-
reactivity [23]. This concentration is also higher in asth-
matics during exacerbation compared with patients with
stable disease [24]. Higher levels of eotaxin in broncho-
alveolar lavage (BAL), increased expression of mRNA
for eotaxin, and an increase of eotaxin in bronchial
epithelium [25] have been found in asthmatics com-
pared with healthy volunteers.
In previous studies, the possibility of measuring of
eotaxin levels in exhaled breath condensate was confirmed
both in children [10] and in adults with asthma [9]. How-
ever, Leung et al did not detect any differences in eotaxin
Figure 2 Correlations between the eotaxin-1 levels and exhaled nitric oxide in studied groups of asthma patients and healthy
volunteers.
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persistent asthma (on inhaled corticosteroids - ICS), inter-
mittent asthma (without ICS) and healthy controls [10].
Ko et al demonstrated that eotaxin levels in EBC were
higher in asthmatics than in controls, but the difference
was no longer evident when, in analysis, steroid naïve mild
asthma patients and healthy controls were taken into con-
sideration [9]. It is worth noting that in any published
study so far, correlations between eotaxin measurements
in EBC and other parameters connected with airway
inflammation - which seem to be necessary for recogniz-
ing the usefulness of this parameter in the assessment of
inflammation - have not been uncovered.
The results of this study have confirmed the possibility
of using eotaxin-1 measurements in EBC. It is worth
noting that, in this study, increased eotaxin-1 levels in
EBC in all groups of asthmatic patients with different
degrees of disease severity compared with healthy volun-
teers were revealed for the first time. These differences
could be the consequence of performing this study in
highly selected groups and the authors have taken
efforts to make this selection as defined as has been
possible. By contrast, in the previouly cited studies, the
differences between studied groups could have been too
minor, and these studies were performed both on atopic
and nonatopic patients and healthy volunteers.
This is the first report which demonstrates the differ-
ences in eotaxin-1 levels between patients with stable
and unstable asthma and healthy volunteers. Our results
are the first report in which it can be shown that con-
centrations of eotaxin-1 in EBC significantly correlate
with exhaled nitric oxide levels - a more and more
appreciable criterion for the evaluation of airway inflam-
mation - in all studied groups of asthma patients
[26-28]. Eotaxin-1 also correlates with other laboratory
tests commonly associated with asthma, such as elevated
levels of eosinophil cationic protein (all studied groups
of asthma patients) and peripheral blood eosinophilia
(unstable ICS-treated asthma and steroid-naïve asthma).
Population studies indicate the presence of a connection
between IgE concentrations and asthma or bronchial
hyperreactivity. The results of our studies did not reveal
Figure 3 Correlations between the eotaxin-1 levels and serum eosinophil cationic protein in studied groups of asthma patients and
healthy volunteers.
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EBC and serum total IgE.
The results obtained here indicate the possibilities of
wider use of eotaxin - 1 measurements in EBC in the
assessment of airway inflammation. The correlations
with other markers recognized in the evaluation of asth-
matic inflammation suggest that, in this way, the possi-
bilities of monitoring the course and treatment of
asthma could be improved.
EBC examination, being simple and non-invasive,
could be exploited to detect specific levels of biomarkers
and monitor the severity of disease in response to
appropriate prescribed therapy [15]. The analysis of EBC
is still in the experimental phase. Many questions con-
cerning the lack of standardization for both the collec-
tion and analysis of EBC, the repeatability of
measurements, and the effect of many factors on con-
centrations of EBC markers, are still not answered.
Figure 4 Correlations between the eotaxin-1 levels and blood eosinophil count in studied groups of asthma patients and healthy
volunteers.
Table 2 Correlations between eotaxin concentrations in EBC and other studied parameters in the groups of asthma
patients and healthy volunteers
Studied groups FENO Serum ECP Blood eosinophil count Serum total IgE Baseline FEV1
Healthy volunteers r = -0.30
p = 0.34
r = 0.05
p = 0.86
r = 0.14
p = 0.66
r = -0.34
p = 0.27
r = -0.52
p = 0.08
Steroid-naïve asthma r = 0.85
p < 0.001
r = 0.80
p < 0.001
r = 0.56
p = 0.03
r = -0.12
p = 0.66
r = -0.18
p = 0.53
Stable asthma ICS-treated r = 0.92
p < 0.001
r = 0.90
p < 0.001
r = 0.27
p = 0.31
r = -0.17
p = 0.52
r = -0.31
p = 0.22
Unstable asthma ICS-treated r = 0.95
p < 0.001
r = 0.95
p < 0.001
r = 0.87
p < 0.001
r = -0.16
p = 0.54
r = -0.18
p = 0.48
Zietkowski et al. Respiratory Research 2010, 11:110
http://respiratory-research.com/content/11/1/110
Page 7 of 10Reports from the EBC Task Force by the major Ameri-
can and European respiratory societies state that,
although dilution may be a factor influencing EBC data,
it does not appear to improve reproducibility. Because
t h em a r k e ru s e dt oc o r r e c tt h ed i f f e r e n c ei nt h ed e g r e e
of dilution has not yet been established, in our study we
have not taken attempts to assess the dilution of ALF in
EBC. EBC volume does not depend on lung function
parameters. There is no evidence to show that changes
in airway caliber cause any difference in mediator
release or dilution of EBC; however, this point is still
under investigations. Cytokine concentrations in EBC
are usually quantified by ELISA kits. Several different
cytokines have been described to be present in EBC: IL
4, 6, 10, 1b,T N F - a [7,15]. However, the concentrations
of several cytokines are around the lower limits of
detection. EBC collection is a completely noninvasive
way of sampling the respiratory tract with good repro-
ducibility in EBC volume and mediator concentration
for several markers: pH, H202, adenosine, 8-isoprostane
[7,15].
Because of the difference in methodological proce-
dures and the effect of many factors described
previously, the results (different concentrations of
eotaxin-1) of our study may not be directly comparable
with the results from other research groups. We suggest
that in the assessment of measurements of concentra-
tions of immunological markers, including chemokines,
in EBC, the control group and analysis of observed
changes between the studied groups, as well as changes
in the studied parameters in time, should be taken into
account.
In contrast to our previous studies, in which we sug-
gested the beneficial effect of inhaled corticosteroids
treatment on downregulation of RANTES in the air-
ways (using EBC) [29], analysis of the results of this
study does not indicate the similar effect of ICS-treat-
ment on eotaxin-1 levels in EBC. Similar observations
were published by Ko et al, which revealed that sub-
jects on high-dose ICS had similar eotaxin levels in
EBC when compared with patients on low-to-moderate
doses of ICS [9]. Feltis et al did not reveal the effects
of three-month treatment with ICS on eotaxin levels in
BAL [4]. Similarly, Tateno et al noted that the plasma
eotaxin level was not altered by inhaled or oral corti-
costeroid treatment [30]. However, in vitro studies
have demonstrated that dexamethasone inhibition of
cytokine-induced eotaxin mRNA augmentation is asso-
ciated with diminished eotaxin secretion in cell cul-
tures [31]. Further studies are needed for a better
Figure 5 Figure of differences in eotaxin-1 levels (measured in duplicates) against the mean, using Bland and Altman statistics in the
studied groups of asthmatic patients and healthy volunteers.
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asthmatic patients.
There are some limitations of the study. One of them
is small number of patients in the studied groups. The
number of patients in particular groups was based on
our experiences from previous studies, in which in simi-
lar numbers of patients the possibility of obtaining sta-
tistically significant differences in studied parameters in
EBC, as well as in peripheral blood, was revealed.
Because of the small sizes of our studied groups, an ana-
lysis of the minimal number of the sample using statisti-
cal tests was not performed. The next limitation of our
study worth noting is the difference in age between the
studied groups of asthmatics and the healthy volunteers.
These differences between studied groups are a conse-
quence of the natural history of asthma, diagnosis at a
young age, and the subsequent, sometimes severe,
course of the disease. Previous studies published by Tar-
gowski et al have shown that age and sex significantly
influence the serum eotaxin levels in healthy people and
patients with rhinoconjunctivitis [32]. However, in the
authors’ opinion, the differences in age observed in this
study between unstable ICS-treated asthma and stable
ICS-treated asthma, as well as between steroid-naïve
asthma and healthy volunteers, are small and irrelevant.
Moreover, observed differences in eotaxin -1 levels
could be rather the consequence of intensification of the
inflammatory process, not of differences in age, and cor-
relate with other markers of airway inflammation.
In conclusion, we have shown that eotaxin-1 levels in
exhaled breath condensate are higher in asthmatic
patients with different degrees of asthma severity when
compared with controls. In patients with unstable
asthma, these values are significantly higher compared
with subjects with stable disease and correlate with
other inflammatory parameters such as exhaled nitric
oxide or serum ECP. Measurements of eotaxin-1 in EBC
of asthma patients may provide another useful diagnos-
tic tool for detecting and monitoring airway inflamma-
tion. However, taking the previously described
methodological limitations of our study into account,
future studies are needed for better assessment of the
clinical significance and the possibility of the practical
usefulness of eotaxin-1 measurements in EBC.
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